Article Versions Notes

Matsumoto H, Watabe T, Igarashi C, Tachibana T, Hihara F, Waki A, Zhang M-R, Tashima H, Yamaya T, Ooe K, et al. Evaluation of ⁶⁴Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates. Pharmaceuticals. 2021; 14(10):950. https://doi.org/10.3390/ph14100950

Matsumoto, Hiroki, Tadashi Watabe, Chika Igarashi, Tomoko Tachibana, Fukiko Hihara, Atsuo Waki, Ming-Rong Zhang, Hideaki Tashima, Taiga Yamaya, Kazuhiro Ooe, and et al. 2021. "Evaluation of ⁶⁴Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates" Pharmaceuticals 14, no. 10: 950. https://doi.org/10.3390/ph14100950

Matsumoto, H., Watabe, T., Igarashi, C., Tachibana, T., Hihara, F., Waki, A., Zhang, M.-R., Tashima, H., Yamaya, T., Ooe, K., Shimosegawa, E., Hatazawa, J., Yoshida, S., Naito, K., Kurihara, H., Ueno, M., Ito, K., Higashi, T., & Yoshii, Y. (2021). Evaluation of ⁶⁴Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates. Pharmaceuticals, 14(10), 950. https://doi.org/10.3390/ph14100950